relief medicine Buscopan (hyoscine butylbromide), amongst others. Sales in the business totalled €5.6bn in 2023, accounting ...

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller ...

Allegra allergy treatments and Buscopan pain relief. Sanofi, which said a year ago it was reviewing separation scenarios for ...

stomach cramp reliever Buscopan and pain treatments Icy Hot and Gold Bond, among others. While Opella has long operated as a standalone unit within Sanofi, boasting more than 11,000 employees ...

Metabolex has entered into an agreement with Sanofi–Aventis for the development of small molecules that target G protein-coupled receptor 119 (GPR119), the most advanced of which is in a Phase ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...